双组分调控系统（和）在[具体物种]对多粘菌素B敏感性中的差异作用 。 需注意，原文中“( and )”以及“.”处信息不完整，翻译时根据常见情况进行了补充说明，实际翻译应依据完整准确的原文内容。
Differential Role of Two-Component Regulatory Systems ( and ) in Polymyxin B Susceptibility of .
作者信息
Owusu-Anim Daniel, Kwon Dong H
机构信息
Department of Biology, Long Island University, New York, USA.
Department of Biology, Long Island University, New York, USA ; Department of Medicine of Michael E DeBakey VA Medical Center, Baylor College of Medicine, Houston, USA.
出版信息
Adv Microbiol. 2012 Mar 1;2(1). doi: 10.4236/aim.2012.21005.
Abstract
Polymyxins are often considered as a last resort to treat multidrug resistant but polymyxin resistance has been increasingly reported worldwide in clinical isolates. Polymyxin resistance in is known to be associated with alterations in either PhoQ or PmrB. In this study, mutant strains of carrying amino acid substitution, a single and/or dual inactivation of PhoQ and PmrB were constructed to further understand the roles of PhoQ and PmrB in polymyxin susceptibility. Polymyxin B resistance was caused by both inactivation and/or amino acid substitutions in PhoQ but by only amino acid substitutions of PmrB. Alterations of both PhoQ and PmrB resulted in higher levels of polymyxin B resistance than alteration of either PhoQ or PmrB alone. These results were confirmed by time-killing assays suggesting that high-level polymyxin resistance in is caused by alterations of both PhoQ and PmrB.
摘要
多粘菌素通常被视为治疗多重耐药菌的最后手段，但全球临床分离株中多粘菌素耐药性的报道日益增多。已知大肠杆菌中的多粘菌素耐药性与PhoQ或PmrB的改变有关。在本研究中，构建了携带氨基酸替代、PhoQ和PmrB单失活和/或双失活的大肠杆菌突变株，以进一步了解PhoQ和PmrB在多粘菌素敏感性中的作用。PhoQ的失活和/或氨基酸替代均可导致多粘菌素B耐药，但只有PmrB的氨基酸替代会导致耐药。PhoQ和PmrB的改变导致的多粘菌素B耐药水平高于单独改变PhoQ或PmrB。时间杀菌试验证实了这些结果，表明大肠杆菌中的高水平多粘菌素耐药是由PhoQ和PmrB的改变引起的。
相似文献
1
Differential Role of Two-Component Regulatory Systems ( and ) in Polymyxin B Susceptibility of .
Adv Microbiol. 2012 Mar 1;2(1). doi: 10.4236/aim.2012.21005.
2
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Dec;53(12):5150-4. doi: 10.1128/AAC.00893-09. Epub 2009 Sep 14.
3
A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa.
FEMS Microbiol Lett. 2009 Sep;298(2):249-54. doi: 10.1111/j.1574-6968.2009.01720.x. Epub 2009 Jul 10.
4
Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Oct;53(10):4345-51. doi: 10.1128/AAC.01267-08. Epub 2009 Jul 27.
5
Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates.
Diagn Microbiol Infect Dis. 2014 Mar;78(3):271-6. doi: 10.1016/j.diagmicrobio.2013.11.027. Epub 2013 Dec 7.
6
PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients.
Antimicrob Agents Chemother. 2012 Feb;56(2):1019-30. doi: 10.1128/AAC.05829-11. Epub 2011 Nov 21.
7
PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.
Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9. doi: 10.1128/AAC.05391-11. Epub 2011 Oct 3.
8
Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.
Mol Microbiol. 2003 Oct;50(1):205-17. doi: 10.1046/j.1365-2958.2003.03673.x.
9
Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa.
mSystems. 2019 Jan 8;4(1). doi: 10.1128/mSystems.00149-18. eCollection 2019 Jan-Feb.
10
Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.
Antimicrob Agents Chemother. 2013 May;57(5):2204-15. doi: 10.1128/AAC.02353-12. Epub 2013 Mar 4.
引用本文的文献
1
Mutational signature analysis predicts bacterial hypermutation and multidrug resistance.
Nat Commun. 2025 Jan 2;16(1):19. doi: 10.1038/s41467-024-55206-w.
2
Colistin: Lights and Shadows of an Older Antibiotic.
Molecules. 2024 Jun 21;29(13):2969. doi: 10.3390/molecules29132969.
3
Keeping up with the pathogens: improved antimicrobial resistance detection and prediction from Pseudomonas aeruginosa genomes.
Genome Med. 2024 Jun 7;16(1):78. doi: 10.1186/s13073-024-01346-z.
4
The PitA protein contributes to colistin susceptibility in Pseudomonas aeruginosa.
PLoS One. 2023 Oct 12;18(10):e0292818. doi: 10.1371/journal.pone.0292818. eCollection 2023.
5
under Acidic Conditions Induces Colistin Resistance through PmrAB Activation and Lipid A Modification.
Antibiotics (Basel). 2023 Apr 26;12(5):813. doi: 10.3390/antibiotics12050813.
6
MvfR Controls Tolerance to Polymyxin B by Regulating in Pseudomonas aeruginosa.
Microbiol Spectr. 2023 Jun 15;11(3):e0042623. doi: 10.1128/spectrum.00426-23. Epub 2023 Apr 11.
7
4F-Indole Enhances the Susceptibility of Pseudomonas aeruginosa to Aminoglycoside Antibiotics.
Microbiol Spectr. 2023 Mar 28;11(2):e0451922. doi: 10.1128/spectrum.04519-22.
8
Genomic variations in polymyxin-resistant Pseudomonas aeruginosa clinical isolates and their effects on polymyxin resistance.
Braz J Microbiol. 2023 Jun;54(2):655-664. doi: 10.1007/s42770-023-00933-3. Epub 2023 Mar 17.
9
Exploring Oceans for Curative Compounds: Potential New Antimicrobial and Anti-Virulence Molecules against .
Mar Drugs. 2022 Dec 23;21(1):9. doi: 10.3390/md21010009.
10
Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance.
Membranes (Basel). 2020 Aug 8;10(8):181. doi: 10.3390/membranes10080181.
本文引用的文献
1
Colistin and polymyxin B: a re-emergence.
Indian J Crit Care Med. 2009 Apr-Jun;13(2):49-53. doi: 10.4103/0972-5229.56048.
2
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Dec;53(12):5150-4. doi: 10.1128/AAC.00893-09. Epub 2009 Sep 14.
3
A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa.
FEMS Microbiol Lett. 2009 Sep;298(2):249-54. doi: 10.1111/j.1574-6968.2009.01720.x. Epub 2009 Jul 10.
4
Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
Int J Antimicrob Agents. 2008 Nov;32(5):450-4. doi: 10.1016/j.ijantimicag.2008.05.016. Epub 2008 Sep 2.
5
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
J Antimicrob Chemother. 2007 Dec;60(6):1206-15. doi: 10.1093/jac/dkm357. Epub 2007 Sep 17.
6
Polymyxin antibiotics for gram-negative infections.
Am J Health Syst Pharm. 2007 Apr 15;64(8):819-26. doi: 10.2146/ajhp060473.
7
Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model.
Antimicrob Agents Chemother. 2007 Jun;51(6):1934-8. doi: 10.1128/AAC.01028-06. Epub 2007 Mar 26.
8
The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections.
Drugs. 2007;67(3):351-68. doi: 10.2165/00003495-200767030-00003.
9
Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Int J Antimicrob Agents. 2007 Jun;29(6):630-6. doi: 10.1016/j.ijantimicag.2006.12.012. Epub 2007 Feb 16.
10
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Antimicrob Agents Chemother. 2007 Feb;51(2):417-22. doi: 10.1128/AAC.00851-06. Epub 2006 Dec 11.
Zotero 插件